Literature DB >> 26990533

The ABCD's of 5'-adenosine monophosphate-activated protein kinase and adrenoleukodystrophy.

Ian Weidling1,2, Russell H Swerdlow1,2,3,4.   

Abstract

This Editorial highlights a study by Singh and coworkers in the current issue of Journal of Neurochemistry, in which the authors present additional evidence that AMPKα1 is reduced in X-linked adrenoleukodystrophy (X-ALD). They make a case for increasing AMPKα1 activity for therapeutic purposes in this disease, and indicate how this goal may be achieved. Read the highlighted article 'Metformin-induced mitochondrial function and ABCD2 up regulation in X-linked adrenoleukodystrophy involves AMP activated protein kinase' on page 86.
© 2016 International Society for Neurochemistry.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26990533      PMCID: PMC5858159          DOI: 10.1111/jnc.13594

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  10 in total

1.  Metformin activates an atypical PKC-CBP pathway to promote neurogenesis and enhance spatial memory formation.

Authors:  Jing Wang; Denis Gallagher; Loren M DeVito; Gonzalo I Cancino; David Tsui; Ling He; Gordon M Keller; Paul W Frankland; David R Kaplan; Freda D Miller
Journal:  Cell Stem Cell       Date:  2012-07-06       Impact factor: 24.633

Review 2.  AMPK: a nutrient and energy sensor that maintains energy homeostasis.

Authors:  D Grahame Hardie; Fiona A Ross; Simon A Hawley
Journal:  Nat Rev Mol Cell Biol       Date:  2012-03-22       Impact factor: 94.444

Review 3.  An energetic tale of AMPK-independent effects of metformin.

Authors:  Russell A Miller; Morris J Birnbaum
Journal:  J Clin Invest       Date:  2010-06-23       Impact factor: 14.808

Review 4.  Cellular and molecular mechanisms of metformin: an overview.

Authors:  Benoit Viollet; Bruno Guigas; Nieves Sanz Garcia; Jocelyne Leclerc; Marc Foretz; Fabrizio Andreelli
Journal:  Clin Sci (Lond)       Date:  2012-03       Impact factor: 6.124

5.  Adrenoleukodystrophy-related protein can compensate functionally for adrenoleukodystrophy protein deficiency (X-ALD): implications for therapy.

Authors:  A Netik; S Forss-Petter; A Holzinger; B Molzer; G Unterrainer; J Berger
Journal:  Hum Mol Genet       Date:  1999-05       Impact factor: 6.150

6.  Long-term effect of bone-marrow transplantation for childhood-onset cerebral X-linked adrenoleukodystrophy.

Authors:  E Shapiro; W Krivit; L Lockman; I Jambaqué; C Peters; M Cowan; R Harris; S Blanche; P Bordigoni; D Loes; R Ziegler; M Crittenden; D Ris; B Berg; C Cox; H Moser; A Fischer; P Aubourg
Journal:  Lancet       Date:  2000-08-26       Impact factor: 79.321

7.  Functional overlap between ABCD1 (ALD) and ABCD2 (ALDR) transporters: a therapeutic target for X-adrenoleukodystrophy.

Authors:  Aurora Pujol; Isidre Ferrer; Carme Camps; Elisabeth Metzger; Colette Hindelang; Noëlle Callizot; Montse Ruiz; Teresa Pàmpols; Marisa Giròs; Jean Louis Mandel
Journal:  Hum Mol Genet       Date:  2004-10-15       Impact factor: 6.150

8.  Loss of AMP-activated protein kinase in X-linked adrenoleukodystrophy patient-derived fibroblasts and lymphocytes.

Authors:  Jaspreet Singh; Shailendra Giri
Journal:  Biochem Biophys Res Commun       Date:  2014-02-01       Impact factor: 3.575

9.  Metformin-induced mitochondrial function and ABCD2 up-regulation in X-linked adrenoleukodystrophy involves AMP-activated protein kinase.

Authors:  Jaspreet Singh; Brittany Olle; Hamid Suhail; Michelle M Felicella; Shailendra Giri
Journal:  J Neurochem       Date:  2016-03-14       Impact factor: 5.372

Review 10.  Repurposing diabetes drugs for brain insulin resistance in Alzheimer disease.

Authors:  Mark Yarchoan; Steven E Arnold
Journal:  Diabetes       Date:  2014-06-15       Impact factor: 9.461

  10 in total
  1 in total

1.  Pharmacodynamic effects of direct AMP kinase activation in humans with insulin resistance and non-alcoholic fatty liver disease: A phase 1b study.

Authors:  Pascale Fouqueray; Sebastien Bolze; Julie Dubourg; Sophie Hallakou-Bozec; Pierre Theurey; Jean-Marie Grouin; Clémence Chevalier; Pascale Gluais-Dagorn; David E Moller; Kenneth Cusi
Journal:  Cell Rep Med       Date:  2021-12-21
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.